Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orthofix acquires intellectual property from IIS
Under the terms of the agreement, Orthofix will pay Intelligent Implant Systems (IIS) up to $7 million for the assignment of the intellectual property and other performance milestones,
Under the terms of the agreement, Orthofix will pay Intelligent Implant Systems (IIS) up to $7 million for the assignment of the intellectual property and other performance milestones,
The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm. The study is expected to be completed by the end of third quarter 2008.
This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent, the company said. Oral and gastrointestinal mucositis is a
This three-month extension allows the FDA time to complete its review. The prasugrel new drug application was granted priority review by the FDA in February 2008. The new
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use in
Sevoflurane, also called fluoromethyl hexafluoroisopropyl ether, is an inhalation anesthetic, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it
The financing will fund the company into 2010 and will be primarily used to drive product development of the company’s initial clinical target, diabetic retinopathy. Under the terms
Under the agreement, Stiefel Laboratories will purchase all of the outstanding shares of Barrier Therapeutics at a price of $4.15 per share in cash, representing a 73% premium
NanoGuardian said that its NanoEncryption technology provides pharmaceutical manufacturers with true forensic, multi-layered, authentication and tracing brand protection at the individual dosage level. NanoGuardian’s NanoEncryption technology works directly
The integrated offering will enable clinical trial patient images to be tracked and managed from within the InForm integrated trial management system, said Phase Forward. The joint solution